Prof. Flavell’s team has shown that nearly all cancer cell types require a specific calcium channel not expressed by normal healthy cells for malignancy. We validated this novel cancer-specific calcium channel as a drug-able target. We now have first-in-class humanized antibodies that specifically block the cancer-specific calcium channel thereby killing cancer cells. Our initial target is non-small cell lung cancer, but because this cancer-specific channel is expressed by virtually all cancers, the blocking antibody will likely treat most cancers. Blavatnik funding is critical by enabling antibody optimization and pre-clinical efficacy testing to generate IP and later enable IND studies.